Survival without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomised Phase 2 Trial in Head and Neck Cancer Patients with Oligometastases using Stereotactic Ablative Radiotherapy (SABR)-alone or chemotherapy SABR.

Fiche publication

Date publication

novembre 2024

Journal

International journal of radiation oncology, biology, physics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian , Dr GUIHARD Sébastien , Dr VERNEREY Dewi , Dr FAIVRE Jean-Christophe , Mr FALCOZ Antoine

Tous les auteurs :
Thariat J, Bosset M, Falcoz A, Vernerey D, Pointreau Y, Racadot S, Faivre JC, Castelli J, Guihard S, Huguet F, Chapet S, Tao Y, Borel C, Fayette J, Rambeau A, Ferrand FR, Pechery A, Bourhis J, Sun XS

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39612953

Résumé

Patients with oligometastasis may have prolonged survival with multisite stereotactic ablative radiotherapy (SABR). Evidence to support this paradigm is scarce in squamous cell carcinomas of the head and neck cancers (HNSCC). The multicentre open-label randomised, GORTEC 2014-04 (NCT03070366) phase II study assesses survival without definitive quality of life (QoL) deterioration of omitting upfront chemotherapy in oligometastatic HNSCC patients by using SABR-alone.